Molecular Tumor Board at the Center for Personalized Medicine Tübingen
NCT ID: NCT03503149
Last Updated: 2018-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2018-03-01
2028-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Individualized Response-adaptive Radiation Dose Prescription in HNC Based on MRI
NCT05160714
Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy
NCT03117946
Rational Therapeutics Based on Matched Tumor and Normal Tissue
NCT02272595
Adaptive Radiotherapy in Patients With Gynecological Tumors
NCT06230549
Registry Study of Proton Radiotherapy in Lymphoma
NCT04613388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To ensure a prospective documentation of all patients who are referred to the Molecular Tumor Board in routine clinical care
* To prospectively ensure the documentation of MTB patients with an emphasis to clinical outcome parameters progression-free survival (PFS), overall survival (OS) and further response assessments (e.g. peripheral immunmonitoring, imaging parameters)
* To prospectively assess patient-reported outcome of MTB patients
* To evaluate compliance to MTB suggestions in routine clinical care
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention
observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥ 18 years of age
* Clinical indication for a referral to Molecular Tumor Board by the treating physician
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ghazaleh Tabatabai, Prof
Role: PRINCIPAL_INVESTIGATOR
University Hospital Tübingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Tübingen
Tübingen, Baden-Wurttemberg, Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZPM-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.